




(86) **Date de dépôt PCT/PCT Filing Date:** 2015/08/20
(87) **Date publication PCT/PCT Publication Date:** 2016/02/25
(85) **Entrée phase nationale/National Entry:** 2017/02/09
(86) **N° demande PCT/PCT Application No.:** US 2015/046160
(87) **N° publication PCT/PCT Publication No.:** 2016/029049
(30) **Priorités/Priorities:** 2014/08/20 (US62/039,620);
2015/07/15 (US62/192,941)

(51) **Cl.Int./Int.Cl.** **C07K 16/28** (2006.01)
(71) **Demandeur/Applicant:**
CYTODYN INC., US
(72) **Inventeurs/Inventors:**
SCHOOLEY, ROBERT T., US;
POURHASSAN, NADER Z., US
(74) **Agent:** PALMER IP INC.

(54) **Titre : THERAPIE PAR ANTICORPS ANTI-VIH COMME TRAITEMENT DE SUBSTITUTION**
(54) **Title: HIV ANTIBODY THERAPY AS TREATMENT SUBSTITUTE**



(57) **Abrégé/Abstract:**
This invention relates to the use of antibody therapy as a treatment substitute, or for treatment interruption, to treat HIV-1 infected patients. Specifically, the present invention relates to the use of antibody therapy, such as PRO 140 monoclonal antibody therapy, as a monotherapy for treatment of HIV-1 infected patients.

CD4 CELL COUNT. COMBINED COHORT 1 AND COHORT 2 SUBJECTS

CD4 CELL COUNT by VISIT																			
Mean 634.8	650.9	618.3	742.6	658.9	658.1	649.7	656.1	679.6	645.0	647.0	762.8	607.7	690.3	758.5	658.7	737.4	582.0	669.8	718.0
Min 304	291	272	443	296	356	330	453	286	403	333	545	291	502	499	310	422	297	503	520
Max 1240	1099	1231	1299	1308	994	1135	847	1182	933	1138	1039	907	1018	1091	1164	1111	824	924	989




FIG. 14

VISIT